These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 15949555

  • 1. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
    Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H.
    Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
    [Abstract] [Full Text] [Related]

  • 2. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.
    Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K.
    Biomaterials; 2005 May; 26(15):2723-32. PubMed ID: 15585276
    [Abstract] [Full Text] [Related]

  • 3. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting.
    Tseng CL, Wang TW, Dong GC, Yueh-Hsiu Wu S, Young TH, Shieh MJ, Lou PJ, Lin FH.
    Biomaterials; 2007 Sep; 28(27):3996-4005. PubMed ID: 17570484
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
    Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, Scopinaro F, Dierckx R, Signore A.
    J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
    [Abstract] [Full Text] [Related]

  • 6. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.
    Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt Cv.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):562-70. PubMed ID: 15120637
    [Abstract] [Full Text] [Related]

  • 7. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
    Tseng CL, Su WY, Yen KC, Yang KC, Lin FH.
    Biomaterials; 2009 Jul 28; 30(20):3476-85. PubMed ID: 19345990
    [Abstract] [Full Text] [Related]

  • 8. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN, Kajimoto K, Akita H, Hyodo M, Ishitsuka T, Harashima H.
    J Control Release; 2010 Oct 15; 147(2):261-8. PubMed ID: 20647023
    [Abstract] [Full Text] [Related]

  • 9. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles.
    Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, Kim Y, Park JH, Kim J, Her S, Oh YK, Kwon IC, Kim K, Jeong SY.
    J Control Release; 2009 May 05; 135(3):259-67. PubMed ID: 19331853
    [Abstract] [Full Text] [Related]

  • 10. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Steinhauser I, Spänkuch B, Strebhardt K, Langer K.
    Biomaterials; 2006 Oct 05; 27(28):4975-83. PubMed ID: 16757022
    [Abstract] [Full Text] [Related]

  • 11. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
    Lin A, Liu Y, Huang Y, Sun J, Wu Z, Zhang X, Ping Q.
    Int J Pharm; 2008 Jul 09; 359(1-2):247-53. PubMed ID: 18457928
    [Abstract] [Full Text] [Related]

  • 12. Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro.
    Yellepeddi VK, Kumar A, Palakurthi S.
    Anticancer Res; 2009 Aug 09; 29(8):2933-43. PubMed ID: 19661298
    [Abstract] [Full Text] [Related]

  • 13. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release.
    Park JS, Han TH, Lee KY, Han SS, Hwang JJ, Moon DH, Kim SY, Cho YW.
    J Control Release; 2006 Sep 28; 115(1):37-45. PubMed ID: 16935380
    [Abstract] [Full Text] [Related]

  • 14. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
    Wang Y, Nakamura K, Liu X, Kitamura N, Kubo A, Hnatowich DJ.
    Bioconjug Chem; 2007 Sep 28; 18(4):1338-43. PubMed ID: 17605463
    [Abstract] [Full Text] [Related]

  • 15. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery.
    Mandal BB, Kundu SC.
    Nanotechnology; 2009 Sep 02; 20(35):355101. PubMed ID: 19671963
    [Abstract] [Full Text] [Related]

  • 16. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
    Ulbrich K, Michaelis M, Rothweiler F, Knobloch T, Sithisarn P, Cinatl J, Kreuter J.
    Int J Pharm; 2011 Mar 15; 406(1-2):128-34. PubMed ID: 21185364
    [Abstract] [Full Text] [Related]

  • 17. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.
    Cancer Res; 2007 Apr 15; 67(8):3927-35. PubMed ID: 17440108
    [Abstract] [Full Text] [Related]

  • 18. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
    Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, Kotlyar A, Baker JR.
    Bioconjug Chem; 2006 Apr 15; 17(5):1109-15. PubMed ID: 16984117
    [Abstract] [Full Text] [Related]

  • 19. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells.
    Matthay KK, Abai AM, Cobb S, Hong K, Papahadjopoulos D, Straubinger RM.
    Cancer Res; 1989 Sep 01; 49(17):4879-86. PubMed ID: 2788031
    [Abstract] [Full Text] [Related]

  • 20. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.
    Acharya S, Dilnawaz F, Sahoo SK.
    Biomaterials; 2009 Oct 01; 30(29):5737-50. PubMed ID: 19631377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.